情绪障碍
氯胺酮
焦虑
心情
医学
精神科
梅德林
心理学
临床心理学
政治学
法学
作者
Gerard Sanacora,Mark A. Frye,William M. McDonald,Sanjay J. Mathew,Mason S. Turner,Alan F. Schatzberg,Paul Summergrad,Charles B. Nemeroff
出处
期刊:JAMA Psychiatry
[American Medical Association]
日期:2017-03-01
卷期号:74 (4): 399-399
被引量:491
标识
DOI:10.1001/jamapsychiatry.2017.0080
摘要
Importance
Several studies now provide evidence of ketamine hydrochloride’s ability to produce rapid and robust antidepressant effects in patients with mood and anxiety disorders that were previously resistant to treatment. Despite the relatively small sample sizes, lack of longer-term data on efficacy, and limited data on safety provided by these studies, they have led to increased use of ketamine as an off-label treatment for mood and other psychiatric disorders. Observations
This review and consensus statement provides a general overview of the data on the use of ketamine for the treatment of mood disorders and highlights the limitations of the existing knowledge. While ketamine may be beneficial to some patients with mood disorders, it is important to consider the limitations of the available data and the potential risk associated with the drug when considering the treatment option. Conclusions and Relevance
The suggestions provided are intended to facilitate clinical decision making and encourage an evidence-based approach to using ketamine in the treatment of psychiatric disorders considering the limited information that is currently available. This article provides information on potentially important issues related to the off-label treatment approach that should be considered to help ensure patient safety.
科研通智能强力驱动
Strongly Powered by AbleSci AI